{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:48:51Z","timestamp":1772808531761,"version":"3.50.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0084866","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T22:27:26Z","timestamp":1390429646000},"page":"e84866","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir\/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00651066","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nguyen Thi Ngoc","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thi Nguyet","family":"Thu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Barrail-Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Hong","family":"Duc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Ngoc","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Laureillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truong","family":"Thi Xuan Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Borand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Quillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Pym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lienhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Huy","family":"Dung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D","family":"Harries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"ref1","unstructured":"UNAIDS (2012) Global Report. UNAIDS Report on the Global AIDS Epidemic."},{"key":"ref2","unstructured":"World Health Organization (2012) Global Tuberculosis Report. WHO, Geneva Switzerland. WHO\/HTM\/TB\/2012.6."},{"key":"ref3","unstructured":"World Health Organization, UNAIDS and UNICEF (2011) Global HIV\/AIDS Response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. WHO, Geneva, Switzerland."},{"key":"ref4","unstructured":"UNAIDS and WHO (2012) The Treatment 2.0 Framework for Action: Catalysing the next phase of treatment, care and support.Geneva, Switzerland."},{"key":"ref5","unstructured":"World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. June 2013. Geneva, Switzerland."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(10)60409-6","article-title":"The HIV-associated tuberculosis epidemic \u2013 when will we act?","volume":"375","author":"AD Harries","year":"2010","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"FX Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"DV Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"SSA Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"ref10","first-page":"WHO\/HTM\/TB\/2009.420","article-title":"Treatment of Tuberculosis. Guidelines","volume":"2010","year":"2010","journal-title":"Fourth Edition"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtld.10.0626","article-title":"Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?","volume":"16","author":"A Loeliger","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials","volume":"40","author":"W Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"AM Baciewicz","year":"2008","journal-title":"Am J Med Sci"},{"key":"ref14","first-page":"1","article-title":"Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations","volume":"47(RR20)","year":"1998","journal-title":"MMWR"},{"key":"ref15","first-page":"1","article-title":"Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors","volume":"53(RR-15)","year":"2004","journal-title":"MMWR"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"C Boulanger","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkp263","article-title":"Pharmacokinetic interactions between rifabutin and lopinavir\/ritonavir in HIV-infected patients with mycobacterial co-infection","volume":"64","author":"H Khachi","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/598336","article-title":"Rifamycin-resistant <italic>Mycobacterium tuberculosis<\/italic> in the highly active antiretroviral therapy era: A report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy","volume":"48","author":"E Jenny-Avital","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"M Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref20","unstructured":"Ministry of Health, Vietnam (2007) Guideline on TB\/HIV Control Collaboration. Hanoi, Vietnam."},{"key":"ref21","unstructured":"Division of AIDS table for grading the severity of adult and pediatric events (2004) Bethesda, MD: National Institute of Allergy and Infectious Diseases. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.niaid.nih.gov\/LabsAndResources\/resources\/DAIDSClinRsrch\/Documents\/daidsaegradingtable.pdf\" xlink:type=\"simple\">http:\/\/www.niaid.nih.gov\/LabsAndResources\/resources\/DAIDSClinRsrch\/Documents\/daidsaegradingtable.pdf<\/ext-link>. Accessed 2013 May 17."},{"key":"ref22","first-page":"310","article-title":"Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus","volume":"75","author":"AM Taburet","year":"2004","journal-title":"Clin PharmacolTher"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/jac\/dkr266","article-title":"Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir","volume":"66","author":"J Zhang","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.00992-10","article-title":"Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects","volume":"55","author":"X Zhang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/AAC.01749-09","article-title":"Pharmacokinetics of darunavir\/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers","volume":"54","author":"V Sekar","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1128\/AAC.00724-07","article-title":"Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects","volume":"52","author":"SL Ford","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","unstructured":"Naiker S, Connolly C, Weisner L, Phillips D, Harries A, <etal>et al<\/etal>. (2012) Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on Lopinavir\/ritonavir-based antiretroviral therapy. Conference on Retroviruses and Opportunistic Infections, Tuesday, Room 312, Abstract#650."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/jac\/dks218","article-title":"Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy","volume":"67","author":"A Matteelli","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref29","unstructured":"World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. Geneva, Switzerland."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5588\/pha.13.0017","article-title":"The ethics of a clinical trial when the protocol clashed with international guidelines","volume":"3","author":"NTN Lan","year":"2013","journal-title":"Public Health Action"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/pgmj.47.553.737","article-title":"Laboratory aspects of intermittent drug therapy","volume":"47","author":"D Mitchison","year":"1971","journal-title":"Postgrad med J"},{"key":"ref32","first-page":"391","article-title":"Rifampicin activity \u201cin vitro\u201d and in established mice","volume":"60","author":"L Verbist","year":"1969","journal-title":"Act Tuberc Pneumol Belg"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokietcis- pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"R Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacteium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"T Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0084866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:44:54Z","timestamp":1588974294000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0084866"}},"subtitle":[],"editor":[{"given":"D. William","family":"Cameron","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0084866","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}